FDA APPROVES REQUIP® XLTM, THE FIRST AND ONLY ORAL ONCE-DAILY NON-ERGOT DOPAMINE AGONIST FOR PARKINSON'S DISEASE Extended-Release Formulation Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients'"Off" Time by Nearly Two Hours Per Day LONDON, UK, 16 June 2008 -- SkyePharma PLC (LSE: SKP) today...
Per capita, American coffee drinkers consume three cups of coffee a day, so you can sleep well -- or stay awake, rather -- knowing that you're not the only one with a caffeine fix.Is it bad for your health? Most reports say no, and they all peg the 'healthy' intake...
Parkinson's Law states that your workload will expand to whatever time you allocate for its completion. Thus, when you're willing to work late or to check on work stuff from your PDA at home, you're usually not really getting more done; instead, you're just being more wasteful with your time. That's...
Byline: Bruce Geiselman Corporations today have a greater responsibility than ever to help solve problems including poverty, global warming and environmental concerns, according to one of the key speakers at this year's Ceres conference. ...
Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The collaboration is focused on developing an emerging class of...
Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme...
FORT LEE, N.J. -- Neurologix, Inc. (OTCBB:NRGX), a biotech company engaged in the research and development of innovative gene therapies for the brain and central nervous system, announced today that the U.S. Food and Drug Administration has granted Fast Track Designation for the company's experimental gene transfer procedure for the...
According to the National Parkinson Foundation NPF, dementia is one of the complications most feared by Parkinson's disease patients and caregivers. Of the 1.5 million Americans living with the disease, an estimated 40% develop dementia.
Byline: Brett Chase At Baxter International Inc. these days, executives worry a little more about making their numbers and a little less about making it home in time for dinner. Known for pleasing work-life advocates and disappointing analysts Byline:...
HAYWARD, Calif. -- IMPAX Laboratories, Inc. (OTC:IPXL) today announced that two poster presentations, highlighting the company's compound, IPX054, a combined immediate- and extended-release carbidopa/levodopa (CD/LD) product to be marketed as VADOVA[TM], were presented at the Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey...
MARIETTA, Ga. -- Solvay Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration FDA has granted Fast Track designation to the development program for levodopa/carbidopa intestinal gel for the potential long-term treatment of motor fluctuations associated with advanced Parkinson's disease.
THE FAST-ACTING nature of Bertek Pharmaceuticals' new drug for Parkinson's disease, Apokyn, was demonstrated on live television after a sufferer agreed to have his treatment shown live on NEC's Today in May.
Gene Logic Inc., of Gaithersburg, a provider of drug development services to pharmaceutical and biotechnology companies, announced that a collaborative study between its Genomics Division and the Mayo Clinic, of Rochester, Minn., has found biomarkers that predict susceptibility to Parkinson's disease, a chronic and progressive movement disorder that affects nearly...
Molecular Biometrics, LLC, a privately held metabolomics company, presented results of a pilot study to identify diagnostic biomarkers for idiopathic Parkinson's Disease PD at the American Academy of Neurology's 59th Annual Meeting in Boston, MA.
Each year, about 50,000 Americans are diagnosed with Parkinson's disease, joining the estimated 1 million people already living in the United States with this serious and disabling brain disorder. Parkinson's occurs when nerve cells become damaged or destroyed in the substantia nigra, an area of the brain that is important...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has received approval from the U.S. Food and Drug Administration FDA for once-daily AZILECTR rasagiline tablets as a treatment for Parkinson's disease both as initial monotherapy in early Parkinson's disease patients and as adjunct therapy to levodopa in...
NEW YORK, May 9 /U.S. Newswire/ -- The U.S. Department of Defense DOD will be collaborating with The Michael J. Fox Foundation for Parkinson's Research MJFF to fund seven proposals in Parkinson's research submitted under the Foundation's Fast Track 20NEW YORK, May 9 /U.S. Newswire/ -- The U.S. Department of...
CAMBRIDGE, Mass. and SAN DIEGO -- Biogen Idec (NASDAQ: BIIB), a global biotechnology leader with products and capabilities in oncology, neurology and immunology, announced today that scientists have discovered that a receptor in the central nervous system CNS may have a specific function in the neurons that degenerate during the...
As Congress moves from setting the broad outlines of the budget to making specific appropriations, members of the Parkinson's Action Network PAN are seeking support for the Army's Neurotoxin Exposure Treatment Research Program, which is primarily As Congress moves from setting the broad outlines...